SARI Announced It Has Entered Into an Agreement to Acquire the 90% Interests in NMS Group
SARI is a Chinese market-leader biotech investment company. - December 30, 2017
Nerviano Medical Sciences Presents Data Regarding a Potent New Cytotoxic Molecule for ADC Generation
NMS-P945 is a potent, innovative and proprietary cytotoxic molecule in the nms pipeline, hbighly suited to conjugation with targeted antibodies. - October 20, 2016
Press Releases 1 - 2 of 2